Chemoradiation therapy for Head Neoplasms

Phase-Based Progress Estimates
1
Effectiveness
2
Safety
Memoral Sloan Kettering Westchester (Limited Protocol Activities), Harrison, NY
Head Neoplasms+8 More
Chemoradiation therapy - Radiation
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

The purpose of this study is to test the treatment approach of de-escalated radiation and chemotherapy followed by a planned neck dissection surgery in people with head and neck cancer. The study will look at how effective the treatment approach is against participants' cancer.

Eligible Conditions

  • Head and Neck Carcinoma
  • Head Neoplasms
  • Head and Neck Cancer
  • Malignant Neoplasms

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

1 Primary · 0 Secondary · Reporting Duration: 2.5 years

2.5 years
Number of participants alive post-Chemo Radiation Therapy

Trial Safety

Safety Progress

2 of 3
This is further along than 68% of similar trials

Trial Design

2 Treatment Groups

Participants with Small Cell Carcinoma Head and Neck Cancer
1 of 2
Participants with Squamous Cell Carcinoma Head and Neck Cancer
1 of 2
Experimental Treatment

36 Total Participants · 2 Treatment Groups

Primary Treatment: Chemoradiation therapy · No Placebo Group · Phase 2

Participants with Small Cell Carcinoma Head and Neck CancerExperimental Group · 3 Interventions: 18F-FMISO PET/CT scan, Carboplatin, Chemoradiation therapy · Intervention Types: DiagnosticTest, Drug, Radiation
Participants with Squamous Cell Carcinoma Head and Neck CancerExperimental Group · 3 Interventions: 18F-FMISO PET/CT scan, Carboplatin, Chemoradiation therapy · Intervention Types: DiagnosticTest, Drug, Radiation
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Carboplatin
2014
Completed Phase 3
~6570

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: 2.5 years
Closest Location: Memoral Sloan Kettering Westchester (Limited Protocol Activities) · Harrison, NY
Photo of new york 1Photo of new york 2Photo of new york 3
2022First Recorded Clinical Trial
0 TrialsResearching Head Neoplasms
1 CompletedClinical Trials

Who is running the clinical trial?

Memorial Sloan Kettering Cancer CenterLead Sponsor
1,806 Previous Clinical Trials
589,292 Total Patients Enrolled
Kaveh Zakeri, MDPrincipal InvestigatorMemorial Sloan Kettering Cancer Center
2 Previous Clinical Trials
200 Total Patients Enrolled

Eligibility Criteria

Age 18+ · All Participants · 10 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You have a histologically confirmed diagnosis of squamous cell carcinoma of the head and neck.
P16 IHC is negative.
You have no evidence of distant metastasis based on staging FDG PET/CT.
You are eligible for the study if you are at least 18 years of age.
You have not received radiation therapy or chemotherapy for HNC.
You have had your primary site tumor removed by surgery but still have residual grossly enlarged, radiographically detectable lymph nodes.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.